Press Releases

Celleron Therapeutics reports 3-year survival data from Phase II clinical trial in MSS colorectal cancer patients treated with zabadinostat and nivolumab combination

Jun 29, 2022

Oxford, UK, 29 June 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announced today a 3-year

Celleron Therapeutics reports over 2-year survival of cancer patient treated with zabadinostat monotherapy

Apr 7, 2022

Oxford, UK, 7 April 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a

Celleron Therapeutics reports survival data from zabadinostat combined with nivolumab in micro-satellite stable colorectal cancer patients

Jan 20, 2022

Oxford UK, 20 January 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a

Celleron Therapeutics Deploys a Digital Pathology Biomarker Platform in Pivotal Colorectal Cancer Clinical Study

Nov 30, 2021

Oxford, UK, 30 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the adoption

Celleron Therapeutics Appoints Corporate Governance Expert, Katherine Innes Ker, To Board

Nov 8, 2021

Oxford, UK, 8 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the

Celleron Therapeutics appoints global financier Richard Taylor as new Board Director

Sep 27, 2021

Oxford, UK, 27th Sep 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the

Celleron Therapeutics announces James Noble as new Board Chairman

Aug 25, 2021

Oxford, August 25, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, today announced that it

Celleron Therapeutics’ CXD101 shows promising clinical results in its China IND programme with partner Nuance Biotech

Jul 6, 2021

Oxford, UK, 6th July 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced encouraging early

Celleron Therapeutics publishes new findings showing immune modulation underpins the anti-cancer effects of zabinostat

Apr 2, 2021

Oxford, April 2nd, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, has worked closely with

Celleron’s Chief Medical Officer David Kerr to Deliver Guest Presentation at WuXi Healthcare Forum 2021

Mar 1, 2021

Oxford, March 1st, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, will be represented by